Uncategorized
AI-Powered Drug Discovery Breakthrough: Charles River and Valo Health Identify Lupus Candidate
Charles River Laboratories, Valo Health, Logica platform, AI-driven drug discovery, lupus treatment, Pioneering Medicines, Flagship Pioneering
Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD
Muscular Dystrophy, Facioscapulohumeral, Epicrispr, Clinical Trials, EPI-321
Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth
Leqembi, Alzheimer’s disease, sales forecast, Eisai, Biogen, revenue projection
BioSpace Presents the World Atlas of GLP-1s
Eli Lilly, Wegovy, India, China, BioSpace, World, Cervical Atlas, GLP-1s, Nordisk, Glucagon-Like Peptide 1, Brazil, India
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
FDA Approves Blujepa: First New Oral Antibiotic for Uncomplicated UTIs in Nearly 30 Years
Gepotidacin, Blujepa, GSK, uncomplicated urinary tract infections (uUTIs), FDA approval, first-in-class antibiotic
Eyeing precision medicines for ocular diseases, Character clinches $93M
Glycogen storage disease type II, Personality Character
Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal
Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement
Hillstar Bio Launches with $67M to Develop Precision Immunotherapies for Autoimmune Diseases
Precision immunology, autoimmune diseases, TRBV9+ T cells, axial spondyloarthritis, Series A funding